Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study

Oncologist

Volumn 17, Issue 10, 2012, Pages 1294-1302

  Lin, Zhong Zhe ^a   Shau, Wen Yi ^b   Shao, Yu Yun ^a   Yang, Yen Yun ^a   Kuo, Raymond Nien Chen ^a,c   Yang, James Chih Hsin ^a,d   Laie, Mei Shu ^a,c,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Center for Drug Evaluation   (Taiwan)

^c Taiwan Cancer Registry   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Adjuvant chemotherapy; Asian ethnicity; Comparative effectiveness; Non small cell lung cancer; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; ASIAN; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TAIWAN; YOUNG ADULT;

EID: 84868114131     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0082     Document Type: Article

References (24)

1. Bordoni R. Consensus conference: Multimodality management of early-and intermediate-stage nonsmall cell lung cancer. The Oncologist 2008;13:945-953.
2. Chhatwani L, Cabebe E, Wakelee HA. Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc 2009;6:194-200.
3. Immerman SC, Vanecko RM, Fry WA et al. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg 1981;32:23-27.
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A metaanalysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
5. Arriagada R, Bergman B, Dunant A et al.; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
6. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 2006;7:719-727.
7. Winton T, Livingston R, Johnson D et al.; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
8. Pignon JP, Tribodet H, Scagliotti GV et al.; LACE Collaborative Group. Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
9. Waller D, Peake MD, Stephens RJ et al. Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-182.
10. Scagliotti GV, Fossati R, Torri V et al.; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA nonsmall-cell lung cancer. J Natl Cancer Inst 2003;95:1453-1461.
11. Pisters KM, Evans WK, Azzoli CG et al.; Cancer Care Ontario; American Society of Clinical Oncology. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007;25:5506-5518.
12. Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009;4:1083-1093.
13. Lin CC, Hsu HH, Sun CT et al. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. J Thorac Oncol 2010;5:1424-1429.
14. Selvaggi G, Scagliotti GV. Perspectives in adjuvant chemotherapy in NSCLC. Expert Rev Respir Med 2007;1:99-110.
15. Taiwan Cancer Registry. Introduction. Available at http://tcr.cph.ntu.edu.tw/main.php?Page_N1, accessed July 12, 2012.
16. Parkin DM, Whelan SL, Ferlay J et al. Cancer Incidence in Five Continents, Volume VIII, No. 155. Lyon, France: IARC Scientific Publications, 2002.
17. Chiang CJ, Chen YC, Chen CJ et al. Cancer trends in Taiwan. Jpn J Clin Oncol 2010;40:897-904.
18. Fritz A, Percy C, Jack A et al. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva, Switzerland: World Health Organization, 2000.
19. Green FL, Page DL, Fleming ID et al. Liver including intrahepatic bile ducts. In: AJCC Cancer Staging Handbook, Sixth Edition. New York: Springer, 2002; 131-144.
20. Strauss GM, Herndon JE 2nd, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol 2008;26:5043-5051.
21. Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: Present and future. Lung Cancer 2008;60(suppl 2):S23-S30.
22. Lin ZZ, Yang CH. Current roles and future perspectives of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Eur J Clin Med Oncol 2010; vol. 2, issue 3.
23. Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-3546.
24. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.